<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Evaluation and treatment of insomnia, daytime sleepiness, and other sleep disorders in Parkinson disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Evaluation and treatment of insomnia, daytime sleepiness, and other sleep disorders in Parkinson disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Evaluation and treatment of insomnia, daytime sleepiness, and other sleep disorders in Parkinson disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lana Chahine, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cathy A Goldstein, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2730871821">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Problems with sleep are among the most common nonmotor symptoms in Parkinson disease (PD). They have important consequences, including reduced quality of life for patients and care partners and exacerbation of other nonmotor and motor symptoms of the disease.
        </p>
        <p>
         Sleep problems are more complex in patients with PD than in many other adults due to the effects of the disease, medications used to treat it, and other interacting factors such as age and comorbidities. Successful treatment requires systematic evaluation and a nuanced, often multifaceted approach to diagnosis and management.
        </p>
        <p>
         Evaluation and management of the most common sleep disorders in patients with PD are reviewed here. Other nonmotor symptoms of PD are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4900.html" rel="external">
          "Management of nonmotor symptoms in Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5089.html" rel="external">
          "Cognitive impairment and dementia in Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2598516931">
         <span class="h1">
          INSOMNIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insomnia is extremely common in patients with PD, affecting 80 percent of patients over the course of the disease [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H355235674">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may have difficulty falling asleep (sleep initiation insomnia), difficulty staying asleep (sleep maintenance insomnia), or a combination of the two [
         <a href="#rid3">
          3
         </a>
         ]. In patients with PD, sleep maintenance insomnia is more common than sleep initiation insomnia [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Patients with sleep initiation insomnia often report trouble falling asleep at the desired bedtime and may lie awake in bed for an extended duration attempting sleep. Patients with sleep maintenance insomnia describe difficulty staying asleep, frequent nighttime awakenings, and/or early morning awakening. Sometimes the complaints are nonspecific, including poor sleep quality, unrefreshing sleep, or daytime sleepiness. (See
         <a class="medical medical_review" href="/z/d/html/7676.html" rel="external">
          "Evaluation and diagnosis of insomnia in adults", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         The distinction between sleep initiation and maintenance insomnia is not formally recognized in the diagnostic criteria  (
         <a class="graphic graphic_table graphicRef117710" href="/z/d/graphic/117710.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ] but is important in considering contributing factors and treatment strategies.
        </p>
        <p class="headingAnchor" id="H915586400">
         <span class="h2">
          Contributing factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many factors contribute to insomnia in PD. While most are more common in advanced disease, all can be seen in early stages, and the etiology of insomnia may vary over the course of the disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nocturnal motor symptoms
         </strong>
         –
         <strong>
         </strong>
         Tremor, rigidity, and dystonia may contribute to both sleep onset and sleep maintenance insomnia [
         <a href="#rid2">
          2,4
         </a>
         ]. Such symptoms may be manifestations of "wearing off" of symptomatic therapies, resulting in re-emergence of motor symptoms at bedtime or during the night. Bradykinesia and rigidity also contribute to impaired bed mobility, which in turn affects the ability to fall and stay asleep [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuropsychiatric symptoms
         </strong>
         –
         <strong>
         </strong>
         Depression, anxiety, and panic disorder are common in patients with PD and may contribute to problems falling and staying asleep [
         <a href="#rid7">
          7-9
         </a>
         ]. Anxiety about sleep itself may be a factor as well. In addition, depression may often present with early morning awakening.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nocturnal psychosis, such as visual hallucinations, can disrupt the sleep of both patients and their bed partners. Nocturnal psychosis can sometimes be difficult to distinguish from dream-related phenomena related to rapid eye movement (REM) sleep behavior disorder (RBD) [
         <a href="#rid10">
          10
         </a>
         ], and neither party may be able to tell whether the patient is asleep or awake. In such cases, psychosis is suggested by the occurrence of symptoms prior to sleep or during periods of awakening during the night.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nocturia and other autonomic problems
         </strong>
         –
         <strong>
         </strong>
         Urinary frequency during the night is common in PD, especially in males, and is often cited as a reason for sleep maintenance insomnia [
         <a href="#rid4">
          4
         </a>
         ]. Contributing factors include primary urologic problems (eg, benign prostatic hypertrophy) as well as PD-related autonomic dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease", section on 'Autonomic dysfunction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other sleep disorders
         </strong>
         – Restless leg syndrome (RLS) can contribute to sleep initiation insomnia, and periodic limb movement disorder (PLMD) and obstructive sleep apnea (OSA) can lead to sleep maintenance insomnia. Some patients with RBD report that the dreams and dream enactment episodes contribute to difficulty staying asleep. (See
         <a class="medical medical_review" href="/z/d/html/4892.html" rel="external">
          "Clinical features and diagnosis of restless legs syndrome and periodic limb movement disorder in adults", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">
          "Rapid eye movement sleep behavior disorder", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nocturnal leg cramps and pain
         </strong>
         – Painful nocturnal cramps, often involving the lower extremities, contribute to insomnia in PD [
         <a href="#rid11">
          11
         </a>
         ]. Other types of pain also affect sleep, including painful sensory symptoms (eg, paresthesias), dystonia, rigidity, and musculoskeletal pain [
         <a href="#rid12">
          12
         </a>
         ]. In some patients, nocturnal pain results from "wearing off" of dopaminergic medications, but in others, pain is present during "on" times as well.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
         – Dopaminergic medications themselves can contribute to poor sleep in PD, especially at higher doses, even though they help treat motor symptoms that contribute to insomnia and can have an independent effect on improving sleep quality [
         <a href="#rid2">
          2,13
         </a>
         ]. (See
         <a class="local">
          'Nocturnal motor symptoms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among PD medications,
         <a class="drug drug_general" data-topicid="9883" href="/z/d/drug information/9883.html" rel="external">
          selegiline
         </a>
         (a monoamine oxidase [MAO] inhibitor),
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         , and
         <a class="drug drug_general" data-topicid="122395" href="/z/d/drug information/122395.html" rel="external">
          istradefylline
         </a>
         (an adenosine antagonist) are particularly likely to affect sleep negatively due to a wake-promoting mechanism of action of the drugs or their metabolites, especially when dosed close to bedtime [
         <a href="#rid2">
          2
         </a>
         ]. By contrast,
         <a class="drug drug_general" data-topicid="10338" href="/z/d/drug information/10338.html" rel="external">
          rasagiline
         </a>
         and
         <a class="drug drug_general" data-topicid="112480" href="/z/d/drug information/112480.html" rel="external">
          safinamide
         </a>
         (both MAO inhibitors) do not seem to affect sleep adversely and may lead to improvements in subjective or objective sleep in a subset of patients [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1233891750">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with PD have at least one cause or contributor to insomnia that can be identified by history, physical examination, and polysomnography  (
         <a class="graphic graphic_table graphicRef50646" href="/z/d/graphic/50646.html" rel="external">
          table 2
         </a>
         ). The goals of the evaluation are to characterize the nature and severity of the sleep problem and identify contributing factors and comorbidities that may be relevant to successful treatment  (
         <a class="graphic graphic_table graphicRef117720" href="/z/d/graphic/117720.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom inventory
         </strong>
         – An insomnia questionnaire can be used to structure the history and ascertain symptoms, severity, comorbidities, and potential etiologies. We prefer to use a PD-specific questionnaire such as the Parkinson's Disease Sleep Scale-2 (PDSS-2), which is available for review purposes
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Feprovide.mapi-trust.org%2Finstruments%2Fparkinson-s-disease-sleep-scale-2%23review_copy&amp;token=gPpuggfpbW1Kz5BI%2FufoaWC9poZ6R7UzqY8nLy2TBN924FCLeDR65nkfMYXsIxN%2BLeSEDem3HerYxSO%2BfCOnICsKljI06mKBQW%2Bw3gLzhsysYlQZDHpHH0FFxik6JOvN&amp;TOPIC_ID=133139" target="_blank">
          online
         </a>
         but requires licensing for clinical use [
         <a href="#rid16">
          16
         </a>
         ], or the Scales for Outcomes in PD-SLEEP (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.movementdisorders.org%2FMDS-Files1%2FPDFs%2FRating-Scales%2FSCOPA-SLEEP_FINAL.pdf&amp;token=gSBFNWD47HPmOl95hbX09uRSuZ7BD5586l4PN3sYZhb9Amc7AwYTWhhYobBtY4ETjtaTx%2Fbt14B9TwJSz1bZAKN3ZfxOwEr6llZQEHz2LhxJw4uBC4XUjLLJtvMSk9zc&amp;TOPIC_ID=133139" target="_blank">
          SCOPA-SLEEP
         </a>
         ), which can be used for clinical purposes with permission from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmds.movementdisorders.org%2Fpublications%2Frating_scales%2Frequest_form.php%3F_ga%3D2.231416671.1703248475.1655222311-1821912428.1655222311&amp;token=hugOGcUj1ypuRxjt6FNf%2F9rgFd94tIkm4x0wih267x5Y5pqEzUpqDFILlUQJUKksCto%2FFsgaffmB2D6EIVllVcd%2Ft56su7qBfq3N%2BDSfAJSKQLTOsx4TH%2FOLEnoq7g25xEi3kl5%2BJs1O8LLJ0jFL9K9WFy31xBV0jGQB%2FLtE%2FyQ%3D&amp;TOPIC_ID=133139" target="_blank">
          Movement Disorders Society
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ]. Questionnaires developed for the general population such as the Pittsburgh Sleep Quality Index (PSQI)  (
         <a class="graphic graphic_table graphicRef106689" href="/z/d/graphic/106689.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef107236" href="/z/d/graphic/107236.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ] and Insomnia Severity Index can also be useful [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep diary
         </strong>
         – We ask patients to maintain a sleep diary  (
         <a class="graphic graphic_table graphicRef87134" href="/z/d/graphic/87134.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_table graphicRef87859" href="/z/d/graphic/87859.html" rel="external">
          table 7
         </a>
         ) for five to seven days and collect information on bedtime, time spent in bed, time spent asleep, awakenings, and the relationship of these to PD medication intake and effects, which in turn may help inform whether "wearing off" of PD medications is contributing to insomnia. (See
         <a class="local">
          'Nocturnal motor symptoms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polysomnography
         </strong>
         – Polysomnography is an important part of the assessment of insomnia in patients with PD and is suggested in all patients  (
         <a class="graphic graphic_table graphicRef55633" href="/z/d/graphic/55633.html" rel="external">
          table 8
         </a>
         ). Its main role is to assess for comorbid primary sleep disorders, including OSA, RBD, and PLMD, which are common reasons for sleep disruption that cannot be diagnosed by history. In-laboratory polysomnography is superior to at-home portable sleep testing for detecting comorbid sleep disorders in PD, but for practical reasons, an in-home portable sleep study may be used as the initial step to assess for OSA. (See
         <a class="medical medical_review" href="/z/d/html/7696.html" rel="external">
          "Overview of polysomnography in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7694.html" rel="external">
          "Home sleep apnea testing for obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A one-night, in-laboratory polysomnogram in a patient with PD may reveal evidence of abnormalities in sleep architecture, such as reduced slow wave sleep and reduced time spent in REM sleep [
         <a href="#rid20">
          20
         </a>
         ]. Total sleep time and sleep efficiency are both reduced in PD compared with controls. However, objective measures of sleep in PD do not always show a strong relationship with subjective sleep concerns, and a normal polysomnogram does not obviate the need for continued systematic evaluation and treatment of poor sleep.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3664175281">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insomnia must be distinguished from circadian rhythm disorders such as delayed sleep-wake phase disorder as well as from RLS, as both can present with difficulty initiating sleep at the desired bedtime  (
         <a class="graphic graphic_table graphicRef117720" href="/z/d/graphic/117720.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7676.html" rel="external">
          "Evaluation and diagnosis of insomnia in adults", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3230708367">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         A practical, stepwise approach to treatment of insomnia in patients with PD is presented in the following sections  (
         <a class="graphic graphic_algorithm graphicRef139922" href="/z/d/graphic/139922.html" rel="external">
          algorithm 1
         </a>
         ). The evidence to support many of the treatment approaches is limited, and treatment decisions should be individualized based on patient characteristics and account for risks and adverse effects.
        </p>
        <p class="headingAnchor" id="H1828701768">
         <span class="h3">
          Assess and treat contributing factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients, we start with systematic assessment and treatment of contributing factors (see
         <a class="local">
          'Contributing factors'
         </a>
         above and
         <a class="local">
          'Evaluation'
         </a>
         above). When medications are prescribed to address contributors to insomnia, preference should be given to medications that can target more than one contributing factor to minimize polypharmacy and adverse effects.
        </p>
        <p class="headingAnchor" id="H3191707674">
         <span class="h4">
          Medications and other sleep disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prescribed and over-the-counter medications should be carefully reviewed. Medications that may be contributing to insomnia should be stopped, where possible, or dosed earlier in the day to reduce effects on nighttime sleep  (
         <a class="graphic graphic_table graphicRef50646" href="/z/d/graphic/50646.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/97867.html" rel="external">
          "Overview of the treatment of insomnia in adults", section on 'Medication side effects'
         </a>
         .)
        </p>
        <p>
         OSA and other comorbid sleep disorders should be treated in parallel to the treatment of all other contributing factors. (See
         <a class="local">
          'Other sleep disorders'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3248282064">
         <span class="h4">
          Nocturnal motor symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with motor symptoms at bedtime or breakthrough motor symptoms overnight, PD medication adjustments are the first step in treatment of insomnia. The duration of effect of
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         and other dopaminergic medications varies from person to person and decreases over the disease course. Thus, a bedtime dose of a PD medication or overnight dosing becomes necessary in some patients. (See
         <a class="medical medical_review" href="/z/d/html/4893.html" rel="external">
          "Medical management of motor fluctuations and dyskinesia in Parkinson disease", section on 'Approach to "wearing off"'
         </a>
         .)
        </p>
        <p>
         There are several ways to provide increased or more steady symptomatic therapy overnight in patients with PD. Selection is individualized according to treatment history and patient and clinical preferences. In the Movement Disorders Society (MDS) treatment guidelines for nonmotor symptoms of PD, the level of evidence to guide choice of PD medications for sleep problems was considered insufficient for the majority of options, with the exception of
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Controlled-release (CR)
         </strong>
         <strong>
          carbidopa-levodopa
         </strong>
         – An evening dose of a
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         CR tablet is useful for nocturnal motor symptoms and may help insomnia secondarily in some patients. In the United States, the carbidopa-levodopa CR formulation is available in 25 mg/100 mg and 50 mg/200 mg tablets. Except in patients whose daytime symptoms are controlled with 100 mg of levodopa per dose, the higher tablet strength of 50 mg/200 mg may be more useful to control nocturnal motor symptoms. Supporting evidence for sleep outcomes is limited, however. In a small placebo-controlled crossover trial in 40 patients with PD and motor fluctuations, a single dose of carbidopa-levodopa CR tablet improved nocturnal motor symptoms but did not have an effect on subjective and objective sleep measures [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some patients, when breakthrough motor symptoms occur during the night despite addition of a CR tablet at bedtime, timed middle-of-the-night dosing of immediate-release levodopa is necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-acting dopamine agonist
         </strong>
         – Long-acting dopamine agonists may be appropriate in some patients with insomnia with nocturnal motor symptoms [
         <a href="#rid21">
          21
         </a>
         ]. They are of particular utility when comorbid RLS is present. All of the dopamine agonists can exacerbate nocturnal psychosis, and they should be avoided in older patients and in younger patients with risk factors for psychosis (eg, cognitive impairment). Dosing and administration are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4896.html" rel="external">
          "Initial pharmacologic treatment of Parkinson disease", section on 'Nonergot dopamine agonists'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Sleep has been examined as an outcome in open-label trials or a secondary outcome in randomized trials of long-acting dopamine agonists (
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          rotigotine
         </a>
         , extended-release
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         , and extended-release
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         ) for treatment of motor symptoms in PD, and all three agents have shown improvements in subjective sleep symptoms as assessed with questionnaires [
         <a href="#rid23">
          23-28
         </a>
         ]. A meta-analysis of eight randomized controlled trials of rotigotine in PD demonstrated an improvement in the sleep item of nonmotor symptoms scale in PD (mean difference -2.2 points, 95% CI -3.08 to -0.98) but nonsignificant differences on other scales [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          On-demand rescue therapies
         </strong>
         – Use of rapid-acting agents such as sublingual or subcutaneous
         <a class="drug drug_general" data-topicid="9374" href="/z/d/drug information/9374.html" rel="external">
          apomorphine
         </a>
         or
         <a class="drug drug_general" data-topicid="120011" href="/z/d/drug information/120011.html" rel="external">
          inhaled levodopa
         </a>
         may be considered for insomnia as well, though their use for nocturnal motor symptoms is guided by limited data. (See
         <a class="medical medical_review" href="/z/d/html/4893.html" rel="external">
          "Medical management of motor fluctuations and dyskinesia in Parkinson disease", section on 'On-demand rescue strategies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Device-assisted and surgical therapies
         </strong>
         – Improved sleep symptoms, including insomnia symptoms, have been shown in randomized trials and open-label studies of all of the device-assisted surgical interventions for advanced PD, including deep brain stimulation [
         <a href="#rid30">
          30,31
         </a>
         ], levodopa intestinal gel [
         <a href="#rid32">
          32
         </a>
         ], and continuous infusion of subcutaneous
         <a class="drug drug_general" data-topicid="9374" href="/z/d/drug information/9374.html" rel="external">
          apomorphine
         </a>
         [
         <a href="#rid33">
          33,34
         </a>
         ]. This is likely in large part due to an improvement in nocturnal motor symptoms. The indications for these therapies are primarily motor and are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4897.html" rel="external">
          "Device-assisted and lesioning procedures for Parkinson disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3469301716">
         <span class="h4">
          Neuropsychiatric comorbidities
         </span>
         <span class="headingEndMark">
          —
         </span>
         When insomnia is a prominent symptom of anxiety, depression, panic disorder, or psychosis, treatment of the neuropsychiatric disorder may or may not result in improved sleep. In some cases, insomnia improves along with other symptoms; in others, insomnia needs to be targeted specifically. The overall approach to treating neuropsychiatric comorbidities in patients with PD is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4900.html" rel="external">
          "Management of nonmotor symptoms in Parkinson disease"
         </a>
         .)
        </p>
        <p>
         Considerations specific to insomnia in patients with PD include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Where an antidepressant is appropriate, sedating medications such as
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         [
         <a href="#rid35">
          35
         </a>
         ],
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         , dosed at bedtime, may be useful, although caution is necessary as these medications can exacerbate RLS and RBD. (See
         <a class="medical medical_review" href="/z/d/html/4900.html" rel="external">
          "Management of nonmotor symptoms in Parkinson disease", section on 'Safety considerations with SSRI use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risks of benzodiazepines in older adults require that these medications are used with great caution, but selective use has a role in some patients with anxiety and insomnia, especially when comorbid RBD is present and has not responded sufficiently to melatonin or when RLS/PLMD requires treatment as well.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          Pimavanserin
         </a>
         , a serotonin 5HT2A receptor inverse agonist/antagonist, is approved for treatment of psychosis in patients with PD. Pooled analysis of two randomized trials of pimavanserin for PD-associated psychosis showed that patients with baseline insomnia complaints had an improvement in their nighttime sleep symptoms as measured with the SCOPA-SLEEP questionnaire [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4900.html" rel="external">
          "Management of nonmotor symptoms in Parkinson disease", section on 'Refractory psychotic symptoms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4183838298">
         <span class="h4">
          Nocturia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nocturia requires evaluation and treatment for primary urologic causes, such as benign prostatic hypertrophy in males. Behavioral modifications, including minimizing intake of fluids close to bedtime and avoiding
         <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">
          caffeine
         </a>
         , may help in some patients.
        </p>
        <p>
         When no underlying structural causes can be identified, bladder relaxant therapies (ie, beta-3 adrenergic agonists and antimuscarinics) are the main pharmacologic option  (
         <a class="graphic graphic_algorithm graphicRef122285" href="/z/d/graphic/122285.html" rel="external">
          algorithm 2
         </a>
         ). Vaginal estrogen may be an additional option in some females.
        </p>
        <p>
         Beta-3 adrenergic agonists (
         <a class="drug drug_general" data-topicid="85675" href="/z/d/drug information/85675.html" rel="external">
          mirabegron
         </a>
         ,
         <a class="drug drug_general" data-topicid="130397" href="/z/d/drug information/130397.html" rel="external">
          vibegron
         </a>
         ) have a more favorable adverse event profile in older adults compared with antimuscarinics, and mirabegron has been studied specifically in patients with PD [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         Among antimuscarinic drugs, those with low central nervous system penetration (eg,
         <a class="drug drug_general" data-topicid="9266" href="/z/d/drug information/9266.html" rel="external">
          darifenacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10313" href="/z/d/drug information/10313.html" rel="external">
          solifenacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10320" href="/z/d/drug information/10320.html" rel="external">
          trospium
         </a>
         ) are preferred in patients with PD due to lower risk of neurocognitive side effects. All antimuscarinics have peripheral anticholinergic side effects that are important to consider in patients with PD (eg, dry mouth, constipation). The MDS guidelines found insufficient evidence to recommend solifenacin for use for urinary frequency in PD but did list it as possibly useful [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Management of nocturia in the general population is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6877.html" rel="external">
          "Nocturia: Clinical presentation, evaluation, and management in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1956134564">
         <span class="h4">
          Other nonmotor symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treating nocturnal pain in PD begins with identifying the etiology, where possible. Some patients experience pain as a "wearing off" phenomenon, and treatment of nocturnal "off" periods is appropriate in these patients, as reviewed above (see
         <a class="local">
          'Nocturnal motor symptoms'
         </a>
         above).
         <a class="drug drug_general" data-topicid="83322" href="/z/d/drug information/83322.html" rel="external">
          Rotigotine
         </a>
         may be useful in patients with "wearing off"-related nocturnal pain [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
         Nocturnal leg cramps are treated as they are in the general population. (See
         <a class="medical medical_review" href="/z/d/html/5177.html" rel="external">
          "Nocturnal leg cramps", section on 'Management'
         </a>
         .)
        </p>
        <p>
         For neuropathic-type pain, gabapentinoids (
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) may be considered, particularly when comorbid RLS is present [
         <a href="#rid41">
          41,42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/88241.html" rel="external">
          "Management of restless legs syndrome and periodic limb movement disorder in adults", section on 'Gabapentinoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H994608968">
         <span class="h3">
          Patients with persistent symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with PD who have persistent insomnia despite treatment of contributing factors and those without contributing factors, the approach to insomnia is similar to that in the general population of older adults. Nonpharmacologic therapies are preferred to medication when feasible and effective, and medications are appropriate in selected patients.
        </p>
        <p>
         Considerations in patients with PD are reviewed here. Treatment guidelines for insomnia in the general population are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/97867.html" rel="external">
          "Overview of the treatment of insomnia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97869.html" rel="external">
          "Cognitive behavioral therapy for insomnia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1281385505">
         <span class="h4">
          Nonpharmacologic therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognitive behavioral therapy for insomnia (CBT-I)
         </strong>
         – CBT-I is recommended as first-line therapy for chronic insomnia in older adults [
         <a href="#rid43">
          43
         </a>
         ] and is suggested in patients with PD as well. Access to therapy can be difficult in some regions and for some patients, but virtual and online delivery methods may overcome some of these barriers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CBT-I is safe, and case series and pilot open-label studies in patients with PD indicate possible benefit [
         <a href="#rid44">
          44,45
         </a>
         ]. In a small trial in which patients were randomly assigned to receive CBT-I (combined with bright light therapy),
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         , or placebo [
         <a href="#rid46">
          46
         </a>
         ], insomnia symptoms improved with both CBT-I and doxepin, but overall quality-of-life measures did not improve. Components and delivery of CBT-I are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/97869.html" rel="external">
          "Cognitive behavioral therapy for insomnia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bright light therapy
         </strong>
         – Bright light therapy has been explored for daytime sleepiness in patients with PD and may also be useful for insomnia [
         <a href="#rid47">
          47-49
         </a>
         ]. In a small, two-week trial comparing bright light (10,000 lux) with a dim-light control (&lt;300 lux) for one hour twice day in 31 patients with PD, both conditions were associated with improved self-reported nighttime sleep symptoms over baseline [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="local">
          'Bright light therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exercise
         </strong>
         – Exercise interventions have been shown to improve both subjective and objective measures of insomnia in patients with PD. Several forms of exercise have been studied in trials, including resistance training, cardiovascular training, balance-focused training, and physical and occupational therapy in combination with exercise.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A systematic review and meta-analysis of the effect of exercise on sleep in PD identified 12 controlled studies, including 10 randomized trials, in a total of 690 patients with PD [
         <a href="#rid50">
          50
         </a>
         ]. There was variability in study design and sleep assessments, but overall, exercise was found to have a positive effect on subjective sleep quality. On subgroup analysis, interventions involving moderate to maximal intensity exercise has greater effects, and the benefit from mild to moderate intensity interventions was not statistically significant. In the only study that included objective sleep measures via polysomnography, the exercise group showed improved sleep efficiency, increased total sleep time, and reduction in wake after sleep onset, although some subjective sleep measures were better in the control group [
         <a href="#rid51">
          51
         </a>
         ]. Such discordance between objective and subjective sleep measures is not unusual in PD and highlights the importance of considering both outcomes when managing insomnia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H667762555">
         <span class="h4">
          Pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         An overview of medications for insomnia is presented separately. Many of the considerations for older adults apply to patients with PD, including increased risk for side effects and avoidance of benzodiazepines unless other treatments have failed. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Special populations'
         </a>
         .)
        </p>
        <p>
         Options for patients with PD include the following medications:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Melatonin
         </strong>
         – Melatonin is suggested as first-line pharmacotherapy for insomnia in most patients with PD, particularly in the presence of comorbid RBD, sleep-onset complaints, or delayed sleep phase. It is generally safe and well tolerated, and several small trials in patients with PD have shown benefit [
         <a href="#rid52">
          52-54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A meta-analysis of seven randomized trials of melatonin in patients with PD demonstrated improvement in subjective sleep quality as assessed by the PSQI and objective sleep as measured by total sleep time on polysomnography, and it was generally safe [
         <a href="#rid54">
          54
         </a>
         ]. Doses in the trials ranged from 2 to 50 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In practice, low doses of melatonin (eg, ≤5 mg) are appropriate for insomnia and delayed sleep phase, as a dose-response effect has not been demonstrated, and doses ≤1 mg may be as effective as higher amounts (see
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Melatonin'
         </a>
         ). Higher doses may be required for RBD  (
         <a class="graphic graphic_table graphicRef96339" href="/z/d/graphic/96339.html" rel="external">
          table 9
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">
          "Rapid eye movement sleep behavior disorder", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9475" href="/z/d/drug information/9475.html" rel="external">
          Ramelteon
         </a>
         , a prescription melatonin analogue, is approved for treatment of sleep-onset insomnia in adults and may be useful in patients with PD, although data are limited and cost sometimes limits use. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Ramelteon'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Doxepin
         </strong>
         – Low doses of
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         , a tricyclic antidepressant, are approved for treatment of insomnia in adults and may be useful in patients with PD as well. However, careful monitoring is required due to the potential for anticholinergic side effects. In a small trial of 18 patients with PD, doxepin 10 mg improved insomnia symptoms compared with placebo as measured by the Insomnia Severity Index (-9 versus -2 point improvement) and other questionnaires [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Low-dose doxepin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Use of nonbenzodiazepine benzodiazepine receptor agonists (BZRAs) such as
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         and
         <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">
          eszopiclone
         </a>
         is discouraged in older adults due to risks of oversedation and falls, and they must be prescribed with caution in patients with PD for these reasons as well as for their risk of complex sleep-related behaviors. Experience with zolpidem in patients with PD specifically is very limited.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The MDS task force on treatment of nonmotor symptoms in PD found insufficient evidence for
         <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">
          eszopiclone
         </a>
         but listed it as possibly useful for insomnia [
         <a href="#rid21">
          21
         </a>
         ]. A small, six-week randomized trial of eszopiclone in 30 patients with PD found that subjective sleep symptoms and nighttime awakenings improved, although total sleep time did not differ compared with placebo [
         <a href="#rid55">
          55
         </a>
         ]. Eszopiclone has the longest half-life of the nonbenzodiazepine BZRAs, and if its use is necessary, it should be used with caution due to increased risk for falls and fractures; the dose should not exceed 2 mg in older adults. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Nonbenzodiazepine BZRAs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         We advise patients
         <strong>
          not
         </strong>
         to use over-the-counter sleep aids containing
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         and other antihistamines because patients with PD are at increased risk for anticholinergic side effects as well as exacerbation of RLS. Sedating antidepressants such as
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         and
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         also carry risks of anticholinergic side effects but may be useful with careful monitoring when comorbid anxiety or depression is present. We do not use benzodiazepines for insomnia unless there are relevant comorbidities (eg, anxiety, RBD) that alter the risk:benefit ratio. (See
         <a class="local">
          'Neuropsychiatric comorbidities'
         </a>
         above.)
        </p>
        <p>
         Other medications that have
         <strong>
          not
         </strong>
         been studied in patients with PD or require more data before use can be endorsed include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium oxybate –
         <a class="drug drug_general" data-topicid="8817" href="/z/d/drug information/8817.html" rel="external">
          Sodium oxybate
         </a>
         (gamma hydroxybutyrate) is a metabolite of gamma-aminobutyric acid (GABA) that is used primarily in the treatment of narcolepsy. Sodium oxybate increases slow wave sleep, and small pilot studies have shown improvements in objective and subjective sleep measures in patients with PD [
         <a href="#rid56">
          56,57
         </a>
         ]. However, it can exacerbate sleep-related breathing disorders and is associated with rapid onset of deep sedation. Therefore, use in patients with PD is not recommended until further safety and efficacy studies have been performed. Use in patients with narcolepsy in the United States requires registration with the Risk Evaluation and Mitigation Strategies (REMS) program. (See
         <a class="medical medical_review" href="/z/d/html/7681.html" rel="external">
          "Treatment of narcolepsy in adults", section on 'Oxybates'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cannabinoids – Preliminary data from small trials indicate that cannabinoids may have efficacy for subjective sleep problems in patients with PD, but more data are needed to better define their role. In a pilot trial of
         <a class="drug drug_general" data-topicid="9995" href="/z/d/drug information/9995.html" rel="external">
          nabilone
         </a>
         , a synthetic cannabinoid, in 19 patients with PD, the nabilone group had improved scores on the sleep item of the Unified Parkinson Disease Rating Scale (UPDRS) compared with the placebo group [
         <a href="#rid58">
          58
         </a>
         ]. Adverse effects occurred in most patients but were mild and transient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dual orexin receptor antagonists – Three dual orexin receptor antagonists (
         <a class="drug drug_general" data-topicid="134764" href="/z/d/drug information/134764.html" rel="external">
          daridorexant
         </a>
         ,
         <a class="drug drug_general" data-topicid="126415" href="/z/d/drug information/126415.html" rel="external">
          lemborexant
         </a>
         , and
         <a class="drug drug_general" data-topicid="96688" href="/z/d/drug information/96688.html" rel="external">
          suvorexant
         </a>
         ) are available in the United States for treatment of insomnia in adults; however, in light of hypothalamic dysfunction and loss of orexin-containing neurons in PD [
         <a href="#rid59">
          59,60
         </a>
         ], they should not be used in patients with PD until safety and efficacy data are available in this population.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2994973298">
         <span class="h1">
          OTHER SLEEP DISORDERS
         </span>
        </p>
        <p class="headingAnchor" id="H337501358">
         <span class="h2">
          REM sleep behavior disorder in PD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia marked by dream enactment behavior and loss of the normal atonia that occurs during REM sleep. It is a highly specific feature of prodromal PD, when it precedes the onset of motor parkinsonism and clinical diagnosis of PD. (See
         <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">
          "Rapid eye movement sleep behavior disorder", section on 'Alpha-synuclein neurodegeneration'
         </a>
         .)
        </p>
        <p>
         In those with established PD, RBD is common, occurring in approximately 60 percent of patients. In this patient population, diagnosis and management considerations are similar to those in the idiopathic RBD population. A polysomnography is useful to confirm the diagnosis by demonstrating loss of normal atonia during REM sleep and rule out RBD mimics such as obstructive sleep apnea (OSA) and periodic limb movement disorder (PLMD) [
         <a href="#rid61">
          61,62
         </a>
         ].
        </p>
        <p>
         Treatment includes institution of safety measures and pharmacotherapy when necessary  (
         <a class="graphic graphic_algorithm graphicRef134977" href="/z/d/graphic/134977.html" rel="external">
          algorithm 3
         </a>
         ). Treatment of comorbid sleep disorders and elimination of exacerbating medications  (
         <a class="graphic graphic_table graphicRef116792" href="/z/d/graphic/116792.html" rel="external">
          table 10
         </a>
         ), such as selective serotonin reuptake inhibitors (SSRIs), is important.
        </p>
        <p>
         Melatonin and
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         are the two first-line therapies for treatment of dream-enactment symptoms in RBD [
         <a href="#rid63">
          63
         </a>
         ]. While there is limited evidence of efficacy for these agents in patients with PD-associated RBD [
         <a href="#rid64">
          64-66
         </a>
         ], studies in patients with PD have been small [
         <a href="#rid54">
          54
         </a>
         ], and in the broader RBD population, melatonin and clonazepam each reduce frequency of dream enactment and increase the duration of REM sleep with atonia [
         <a href="#rid63">
          63
         </a>
         ]. Melatonin is typically preferred for initial therapy based on lower risk of side effects  (
         <a class="graphic graphic_algorithm graphicRef134977" href="/z/d/graphic/134977.html" rel="external">
          algorithm 3
         </a>
         ). Use of clonazepam warrants careful monitoring in patients with PD given the older age and increased risk of falls in this group. (See
         <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">
          "Rapid eye movement sleep behavior disorder", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
         The effect of dopaminergic medications on RBD symptoms varies. Some patients with RBD experience a reduction in dream-enactment episodes following initiation of levodopa, dopamine agonists, or monoamine oxidase (MAO) inhibitors, while others having an exacerbation [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3069283725">
         <span class="h2">
          Restless legs syndrome and periodic limb movement disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Restless legs syndrome (RLS) and PLMD are sleep-related movement disorders. RLS is common in PD, occurring in approximately 15 percent of PD patients [
         <a href="#rid67">
          67
         </a>
         ]. The diagnostic criteria for RLS  (
         <a class="graphic graphic_table graphicRef86837" href="/z/d/graphic/86837.html" rel="external">
          table 11
         </a>
         ) and PLMD  (
         <a class="graphic graphic_table graphicRef86839" href="/z/d/graphic/86839.html" rel="external">
          table 12
         </a>
         ) are the same in PD as in the general population, but there are a few diagnostic considerations that are unique to PD. Notably, PLMD is highly difficult to diagnose in patients with PD as a diagnosis of PLMD requires both periodic limb movements of sleep (PLMS)
         <em>
         </em>
         <strong>
          and
         </strong>
         sleep disturbance or daytime dysfunction that cannot be attributed to another factor.
        </p>
        <p>
         Up to 40 percent of patients with PD have nocturnal leg restlessness, which is distinguished from typical RLS in that the symptoms do not follow the diurnal variation of RLS and are not clearly relieved with movement [
         <a href="#rid68">
          68,69
         </a>
         ]. In addition, leg restlessness is a "wearing off" symptom in some patients [
         <a href="#rid70">
          70
         </a>
         ]; in such cases, strategies for "wearing off" are appropriate for first-line management. (See
         <a class="medical medical_review" href="/z/d/html/4893.html" rel="external">
          "Medical management of motor fluctuations and dyskinesia in Parkinson disease", section on 'Approach to "wearing off"'
         </a>
         .)
        </p>
        <p>
         Comorbid PLMD appears to be less common in patients with PD compared with the general population, but its diagnosis and management are the same [
         <a href="#rid71">
          71,72
         </a>
         ].
        </p>
        <p>
         There is limited evidence to guide treatment of RLS and PLMD in patients with PD, but the approach is generally similar to that in the older adult population  (
         <a class="graphic graphic_algorithm graphicRef131282" href="/z/d/graphic/131282.html" rel="external">
          algorithm 4
         </a>
         ). When RLS co-occurs with evening/nocturnal motor symptoms, a long-acting dopamine agonist or levodopa are typically used to target both syndromes. Gabapentinoids (
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="16486" href="/z/d/drug information/16486.html" rel="external">
          gabapentin enacarbil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) are first-line therapies for patients already receiving dopaminergic medications, who are not having "wearing off" effects, and especially when comorbid nocturnal pain is present.
        </p>
        <p>
         Treatment of RLS is reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/88241.html" rel="external">
          "Management of restless legs syndrome and periodic limb movement disorder in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H656348957">
         <span class="h2">
          Sleep-related breathing disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Underlying brain disease may make patients with PD particularly vulnerable to the consequences of OSA, including excessive daytime sleepiness (EDS) and cognitive dysfunction [
         <a href="#rid73">
          73-75
         </a>
         ].
        </p>
        <p>
         The presentation, diagnosis, and management of OSA and other sleep-related breathing disorders are largely similar for patients with PD compared with the general population. However, there are a few considerations specific to the PD population.
        </p>
        <p>
         Restrictive pulmonary disease related to rigidity and bradykinesia has been hypothesized as a risk factor for sleep-related breathing disorders in patients with PD. While rates of OSA are similar to those in the general population, for a given body mass index (BMI), patients with PD may be at higher risk for OSA, perhaps due to these pulmonary factors [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Diagnostic sleep testing should be performed in patients with EDS or snoring [
         <a href="#rid77">
          77,78
         </a>
         ]. However, limiting testing to these patients will miss patients with OSA, as studies in patients with PD have found that neither subjective sleepiness nor snoring are predictive of sleep apnea [
         <a href="#rid73">
          73,77,79,80
         </a>
         ].
        </p>
        <p>
         On polysomnography, patients with PD have less severe desaturations during apneas for a given level of OSA severity (as measured by apnea hypopnea index [AHI]), and they are more likely to have respiratory effort-related arousals (RERAs), which are not detected on home sleep apnea testing (HSAT) [
         <a href="#rid81">
          81
         </a>
         ]. Thus, in a patient for whom there is suspicion for OSA but for whom HSAT is negative, in-laboratory polysomnography should be obtained. (See
         <a class="medical medical_review" href="/z/d/html/7694.html" rel="external">
          "Home sleep apnea testing for obstructive sleep apnea in adults", section on 'Limitations'
         </a>
         .)
        </p>
        <p>
         Treatment of OSA can improve mean sleep latency, subjective sleepiness, and other important signs and symptoms, including cognition, in at least a subset of patients with PD [
         <a href="#rid82">
          82
         </a>
         ]. Positive airway pressure therapy is the mainstay of therapy, as discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">
          "Obstructive sleep apnea: Overview of management in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1593975741">
         <span class="h2">
          Circadian rhythm disruption
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PD are at risk for abnormalities in endogenous circadian rhythms resulting from involvement of circadian structures by the neurodegenerative disease process. The amplitude of melatonin secretion may be reduced in individuals with PD taking dopaminergic medications, especially those with daytime sleepiness [
         <a href="#rid83">
          83,84
         </a>
         ].
        </p>
        <p>
         Circadian rhythm disorders such as advanced sleep phase and delayed sleep phase may be seen in PD and are managed as they are in the general population. (See
         <a class="medical medical_review" href="/z/d/html/97844.html" rel="external">
          "Overview of circadian rhythm sleep-wake disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1802106797">
         <span class="h1">
          EXCESSIVE DAYTIME SLEEPINESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excessive daytime sleepiness (EDS) is common in PD, occurring in at least one-third of patients, and increases with advancing age and disease duration [
         <a href="#rid85">
          85,86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2282596631">
         <span class="h2">
          Evaluation and initial treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         EDS may present with a range of severity, from subjective sleepiness to irresistible urge to sleep regardless of the situation and circumstances. This can affect quality of life and can be dangerous in situations such as driving.
        </p>
        <p>
         The etiology of EDS in PD may be multifactorial, although involvement of wake-promoting structures by the neurodegenerative process accounts for at least some of the propensity. Exogenous factors also contribute and are important to identify and modify:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduce dopamine agonists
         </strong>
         – Dopaminergic medications are an important cause of sleepiness in patients with PD. Dopamine agonists are most likely to cause EDS, but levodopa can as well [
         <a href="#rid2">
          2
         </a>
         ]. Dopamine agonists should be reduced or eliminated as a first-line step, when possible, especially for patients on higher doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A variety of other medications can cause EDS, including opioids, antiseizure medications, and certain antihypertensives. (See
         <a class="medical medical_review" href="/z/d/html/97865.html" rel="external">
          "Excessive daytime sleepiness due to medical disorders and medications", section on 'Medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treat nocturnal
         </strong>
         <strong>
          sleep disorders
         </strong>
         – Subjective and objective measures of nocturnal sleep often do
         <strong>
          not
         </strong>
         explain EDS in PD [
         <a href="#rid87">
          87
         </a>
         ]. At least in a subset of patients, however, a nocturnal sleep disorder such as OSA may account for EDS [
         <a href="#rid88">
          88,89
         </a>
         ], and its treatment may improve symptoms. Thus, evaluation and optimization of nocturnal sleep is part of the management approach [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Assess and treat contributing factors'
         </a>
         above and
         <a class="local">
          'Other sleep disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychiatric and medical comorbidities
         </strong>
         – EDS is a manifestation of depression in some patients. Medical comorbidities are important to consider as well, such as chronic lung disease and chronic pain, which frequently disrupt sleep. (See
         <a class="medical medical_review" href="/z/d/html/97865.html" rel="external">
          "Excessive daytime sleepiness due to medical disorders and medications", section on 'Medical conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient education and safety
         </strong>
         – EDS raises important considerations related to driving safety and other activities. Driving cessation may be appropriate in certain patients. Prevention and countermeasures related to drowsy driving are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/101086.html" rel="external">
          "Drowsy driving: Risks, evaluation, and management", section on 'Driver education'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1529296716">
         <span class="h2">
          Bright light therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with persistent EDS despite treatment of contributing factors, we suggest bright light therapy. Exposure to bright light, such as 10,000 lux for 60 minutes per day, improves daytime sleepiness in the general population and appears to be useful in patients with PD as well. In a meta-analysis of five trials in a total of 92 patients with PD and EDS, bright light therapy led to small but significant improvements in daytime function scores [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Light boxes are commercially available in various wavelengths and intensities. We generally advise patients to use a broad-spectrum white light box. The recommended distance from the source is dependent on the intensity of emitted light, and instructions for distance are typically provided by the manufacturer (eg, 10,000 lux at 5 feet). The light box should be used every morning for two to four weeks for a sufficient trial. Patients who derive benefit can continue as maintenance therapy.
        </p>
        <p class="headingAnchor" id="H238678947">
         <span class="h2">
          Exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Structured physical activity and exercise also hold promise as a treatment for daytime sleepiness in PD, but evidence to guide specific exercise prescriptions is lacking [
         <a href="#rid90">
          90
         </a>
         ]. In general, patients with PD should be encouraged to meet the recommendations of physical activity for adults. A useful
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nia.nih.gov%2Fhealth%2Freal-life-benefits-exercise-and-physical-activity&amp;token=tpSvKVkVpLt2Rr4sJewIXgUn6vp%2B9bKUTDx7nn4wvDyiWZbWLLKUwF1zylpGrXyxUcUcY%2B%2BkBK7pZxO6wDYEM%2Fg682i1KaU%2Btt6FQ4JgRlk%3D&amp;TOPIC_ID=133139" target="_blank">
          online resource
         </a>
         for patients is available from the National Institute on Aging [
         <a href="#rid91">
          91
         </a>
         ]. Exercise likely has benefits similar to those seen in the general adult population and may benefit other aspects specific to PD, including EDS.
        </p>
        <p class="headingAnchor" id="H2546781257">
         <span class="h2">
          Wake-promoting agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wake-promoting agents have limited evidence for efficacy in PD but may be tried in select patients who do not respond to other interventions and desire a trial of medication. Options include
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         [
         <a href="#rid21">
          21,92
         </a>
         ],
         <a class="drug drug_general" data-topicid="9260" href="/z/d/drug information/9260.html" rel="external">
          armodafinil
         </a>
         [
         <a href="#rid93">
          93
         </a>
         ], tomoxetine [
         <a href="#rid94">
          94
         </a>
         ],
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         [
         <a href="#rid95">
          95
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">
          caffeine
         </a>
         [
         <a href="#rid96">
          96,97
         </a>
         ]. It is important to set expectations; any benefit, when present, is usually mild and may not be sustained [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Even for
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         , which is the best studied agent, data are sparse and conflicting [
         <a href="#rid21">
          21,92,98-100
         </a>
         ]. Some studies have suggested that modafinil may lead to subjective improvement in daytime sleepiness in some patients with PD [
         <a href="#rid98">
          98,99
         </a>
         ], though efficacy on objective measures has not been demonstrated. In the largest of these small trials, 40 patients with PD and EDS were randomly assigned to treatment with modafinil in doses of 200 to 400 mg/day or placebo [
         <a href="#rid100">
          100
         </a>
         ]. There was no benefit for modafinil treatment in the primary outcome measure, the ESS (
         <a class="calc calc_professional" href="/z/d/html/13440.html" rel="external">
          calculator 1
         </a>
         ), or any of the secondary outcome measures.
        </p>
        <p>
         Other medications used for sleepiness in patients with narcolepsy are of uncertain benefit in PD. A placebo-controlled crossover trial of
         <a class="drug drug_general" data-topicid="120816" href="/z/d/drug information/120816.html" rel="external">
          solriamfetol
         </a>
         , a dopamine-norepinephrine reuptake inhibitor used in patients with narcolepsy, found no major safety concerns but did not find evidence for subjective or objective improvements in sleepiness in 66 patients with PD; additional studies are needed [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8817" href="/z/d/drug information/8817.html" rel="external">
          Sodium oxybate
         </a>
         , which enhances slow wave sleep, has been associated with improvements in EDS in an open-label study [
         <a href="#rid57">
          57
         </a>
         ] and in a randomized trial of 12 patients with PD-associated EDS [
         <a href="#rid56">
          56
         </a>
         ]. However, exacerbation of sleep apnea occurred in a subset of patients. Based on the small amount of available data and the safety concerns, additional studies are needed before we would suggest using sodium oxybate in patients with PD.
        </p>
        <p class="headingAnchor" id="H2849589848">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112949.html" rel="external">
          "Society guideline links: Restless legs syndrome"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117215.html" rel="external">
          "Society guideline links: Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3944782089">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15524.html" rel="external">
          "Patient education: Parkinson disease (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16177.html" rel="external">
          "Patient education: Insomnia (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/85720.html" rel="external">
          "Patient education: Daytime sleepiness (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16178.html" rel="external">
          "Patient education: Sleep apnea in adults (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86220.html" rel="external">
          "Patient education: What is a sleep study? (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16243.html" rel="external">
          "Patient education: Restless legs syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/728.html" rel="external">
          "Patient education: Parkinson disease symptoms and diagnosis (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/731.html" rel="external">
          "Patient education: Parkinson disease treatment options — medications (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2339107079">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/132685.html" rel="external">
          "Patient perspective: Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1193348421">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Insomnia
         </strong>
         – Insomnia affects at least 80 percent of patients with Parkinson disease (PD) over the course of the disease. Patients may report difficulty falling asleep (sleep-onset insomnia), staying asleep (sleep-maintenance insomnia), or both  (
         <a class="graphic graphic_table graphicRef117710" href="/z/d/graphic/117710.html" rel="external">
          table 1
         </a>
         ); sleep maintenance problems are the most common. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Contributing factors
         </strong>
         – The most common contributing factors in patients with PD are nocturnal motor symptoms ("wearing off"), neuropsychiatric symptoms, nocturia, other sleep disorders, nocturnal leg cramps and pain, and medication side effects. (See
         <a class="local">
          'Contributing factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Evaluation
         </strong>
         – History and physical examination should characterize the nature and severity of the sleep problem and identify contributing factors and comorbidities that may be relevant to successful treatment  (
         <a class="graphic graphic_table graphicRef117720" href="/z/d/graphic/117720.html" rel="external">
          table 3
         </a>
         ). Polysomnography should be performed to assess for comorbid sleep disorders. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management
         </strong>
         – Treatment begins with assessment and treatment of contributing factors, including disease-related factors (eg, "wearing off" at bedtime or overnight), comorbid depression and anxiety, nocturia, and other sleep disorders  (
         <a class="graphic graphic_algorithm graphicRef139922" href="/z/d/graphic/139922.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Assess and treat contributing factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For persistent insomnia, the approach is similar to that in the general population of older adults. Cognitive behavioral therapy for insomnia (CBT-I) is preferred to medication when feasible and effective, and medications are appropriate in selected patients. (See
         <a class="local">
          'Nonpharmacologic therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Among medications, we suggest melatonin as first-line therapy in most patients with PD (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). It is generally safe and well tolerated, and several small trials in patients with PD have shown benefit. Alternatives include low-dose
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         and, with caution,
         <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">
          eszopiclone
         </a>
         or
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         . We suggest
         <strong>
          not
         </strong>
         using duel orexin receptor antagonists due to the potential to exacerbate hypothalamic dysfunction in PD (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Pharmacotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rapid eye movement (REM) sleep behavior disorder (RBD)
         </strong>
         – RBD is common in both prodromal PD and fully manifest disease. Treatment involves establishing a safe sleeping environment and use of melatonin or
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         to suppress movements  (
         <a class="graphic graphic_algorithm graphicRef134977" href="/z/d/graphic/134977.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="local">
          'REM sleep behavior disorder in PD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Restless legs syndrome (RLS)
         </strong>
         – RLS is common in PD and often disrupts sleep initiation and quality of life  (
         <a class="graphic graphic_algorithm graphicRef131282" href="/z/d/graphic/131282.html" rel="external">
          algorithm 4
         </a>
         ). RLS should be distinguished from leg restlessness that does not follow a diurnal pattern and from symptoms of "wearing off." (See
         <a class="local">
          'Restless legs syndrome and periodic limb movement disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep-related breathing disorders
         </strong>
         – Patients with PD may be at higher risk for obstructive sleep apnea (OSA) than the general population when adjusted for body mass index (BMI). Polysomnogram is preferred for diagnostic confirmation of OSA. Home sleep apnea testing (HSAT) may have poor sensitivity for OSA in patients with PD, and a negative study should prompt in-laboratory polysomnography. (See
         <a class="local">
          'Sleep-related breathing disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Excessive daytime sleepiness (EDS)
         </strong>
         – Dopamine agonists are an important cause of EDS in patients with PD and should be reduced or discontinued when possible. Other sleep disorders should be assessed and treated. (See
         <a class="local">
          'Evaluation and initial treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with persistent EDS despite treatment of contributing factors, we suggest bright light therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Judicious use of
         <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">
          caffeine
         </a>
         during the day, or pharmacologic treatment with
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         or
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         , may offer some benefit when nonpharmacologic options have failed.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chahine LM, Amara AW, Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. Sleep Med Rev 2017; 35:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP. Insomnia in Parkinson's disease: frequency and progression over time. J Neurol Neurosurg Psychiatry 2007; 78:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gómez-Esteban JC, Zarranz JJ, Lezcano E, et al. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. Mov Disord 2006; 21:983.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, text revision, American Academy of Sleep Medicine, 2023.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Louter M, van Sloun RJ, Pevernagie DA, et al. Subjectively impaired bed mobility in Parkinson disease affects sleep efficiency. Sleep Med 2013; 14:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki K, Miyamoto M, Miyamoto T, et al. Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord 2009; 15:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbaan D, van Rooden SM, Visser M, et al. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. Mov Disord 2008; 23:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutten S, Vriend C, van der Werf YD, et al. The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease. Parkinsonism Relat Disord 2017; 39:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgante L, Colosimo C, Antonini A, et al. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry 2012; 83:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhawan V, Dhoat S, Williams AJ, et al. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. J Neurol Sci 2006; 248:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Martin P, Rizos AM, Wetmore JB, et al. Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. Mov Disord Clin Pract 2019; 6:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chahine LM, Daley J, Horn S, et al. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease. Parkinsonism Relat Disord 2013; 19:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrempf W, Fauser M, Wienecke M, et al. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial. Eur J Neurol 2018; 25:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plastino M, Gorgone G, Fava A, et al. Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study. J Clin Neurosci 2021; 91:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Kohnen R, Högl B, et al. Parkinson's disease sleep scale--validation of the revised version PDSS-2. Mov Disord 2011; 26:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marinus J, Visser M, van Hilten JJ, et al. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003; 26:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Högl B, Arnulf I, Comella C, et al. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord 2010; 25:2704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Ren R, Sanford LD, et al. Sleep in Parkinson's disease: A systematic review and meta-analysis of polysomnographic findings. Sleep Med Rev 2020; 51:101281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord 2019; 34:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stocchi F, Barbato L, Nordera G, et al. Sleep disorders in Parkinson's disease. J Neurol 1998; 245 Suppl 1:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol 2012; 19:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiang W, Sun YQ, Teoh HC. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des Devel Ther 2018; 12:2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Kies B, Dioszeghy P, et al. Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: Results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia 2012; 2:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giladi N, Fichtner A, Poewe W, Boroojerdi B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm (Vienna) 2010; 117:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang HT, Wang L, He Y, Yu G. Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials. J Neurol Sci 2018; 393:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eugster L, Bargiotas P, Bassetti CL, Michael Schuepbach WM. Deep brain stimulation and sleep-wake functions in Parkinson's disease: A systematic review. Parkinsonism Relat Disord 2016; 32:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jost ST, Ray Chaudhuri K, Ashkan K, et al. Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. J Parkinsons Dis 2021; 11:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zibetti M, Rizzone M, Merola A, et al. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol Scand 2013; 127:e28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2015; 30:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Cock VC, Dodet P, Leu-Semenescu S, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol 2022; 21:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werneck AL, Rosso AL, Vincent MB. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. Arq Neuropsiquiatr 2009; 67:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel N, LeWitt P, Neikrug AB, et al. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis. Clin Neuropharmacol 2018; 41:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moussa M, Chakra MA, Dabboucy B, et al. The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial. Scand J Urol 2022; 56:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho SY, Jeong SJ, Lee S, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn 2021; 40:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rascol O, Zesiewicz T, Chaudhuri KR, et al. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. J Clin Pharmacol 2016; 56:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buhmann C, Kassubek J, Jost WH. Management of Pain in Parkinson's Disease. J Parkinsons Dis 2020; 10:S37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmann J, Allen RP, Högl B, et al. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§. Mov Disord 2018; 33:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauk L. Treatment of Chronic Insomnia in Adults: ACP Guideline. Am Fam Physician 2017; 95:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebrun C, Gély-Nargeot MC, Rossignol A, et al. Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson's disease: A focus on psychological and daytime functioning with a single-case design with multiple baselines. J Clin Psychol 2020; 76:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Findley J, Hernandez-Con M, Chahine LM. Cognitive behavioral therapy for insomnia in Parkinson's disease: a case series. NPJ Parkinsons Dis 2017; 3:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study. Parkinsonism Relat Disord 2013; 19:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino JK, Freelance CB, Willis GL. The effect of light exposure on insomnia and nocturnal movement in Parkinson's disease: an open label, retrospective, longitudinal study. Sleep Med 2018; 44:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Videnovic A, Klerman EB, Wang W, et al. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2017; 74:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin F, Su Y, Weng Y, et al. The effects of bright light therapy on depression and sleep disturbances in patients with Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. Sleep Med 2021; 83:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cristini J, Weiss M, De Las Heras B, et al. The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis. Sleep Med Rev 2021; 55:101384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amara AW, Wood KH, Joop A, et al. Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease. Mov Disord 2020; 35:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 2007; 254:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005; 6:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma H, Yan J, Sun W, et al. Melatonin Treatment for Sleep Disorders in Parkinson's Disease: A Meta-Analysis and Systematic Review. Front Aging Neurosci 2022; 14:784314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menza M, Dobkin RD, Marin H, et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord 2010; 25:1708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büchele F, Hackius M, Schreglmann SR, et al. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2018; 75:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ondo WG, Perkins T, Swick T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 2008; 65:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peball M, Krismer F, Knaus HG, et al. Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. Ann Neurol 2020; 88:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Compta Y, Santamaria J, Ratti L, et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 2009; 132:3308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breen DP, Nombela C, Vuono R, et al. Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Mov Disord 2016; 31:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaig C, Iranzo A, Pujol M, et al. Periodic Limb Movements During Sleep Mimicking REM Sleep Behavior Disorder: A New Form of Periodic Limb Movement Disorder. Sleep 2017; 40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iranzo A, Santamaría J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep 2005; 28:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010; 6:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilat M, Coeytaux Jackson A, Marshall NS, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. Mov Disord 2020; 35:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin C, Park H, Lee WW, et al. Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. J Neurol Sci 2019; 401:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn JH, Kim M, Park S, et al. Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial. Parkinsonism Relat Disord 2020; 75:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang X, Liu B, Shen H, et al. Prevalence of restless legs syndrome in Parkinson's disease: a systematic review and meta-analysis of observational studies. Sleep Med 2018; 43:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki K, Okuma Y, Uchiyama T, et al. Characterizing restless legs syndrome and leg motor restlessness in patients with Parkinson's disease: A multicenter case-controlled study. Parkinsonism Relat Disord 2017; 44:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gjerstad MD, Tysnes OB, Larsen JP. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 2011; 77:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuzuhara S, Kokubo Y. Atypical parkinsonism of Japan: amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): an update. Mov Disord 2005; 20 Suppl 12:S108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loo HV, Tan EK. Case-control study of restless legs syndrome and quality of sleep in Parkinson's disease. J Neurol Sci 2008; 266:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prudon B, Duncan GW, Khoo TK, et al. Primary sleep disorder prevalence in patients with newly diagnosed Parkinson’s disease. Mov Disord 2014; 29:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neikrug AB, Maglione JE, Liu L, et al. Effects of sleep disorders on the non-motor symptoms of Parkinson disease. J Clin Sleep Med 2013; 9:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elfil M, Bahbah EI, Attia MM, et al. Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease. Mov Disord 2021; 36:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maggi G, Trojano L, Barone P, Santangelo G. Sleep Disorders and Cognitive Dysfunctions in Parkinson's Disease: A Meta-Analytic Study. Neuropsychol Rev 2021; 31:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun AP, Liu N, Zhang YS, et al. The relationship between obstructive sleep apnea and Parkinson's disease: a systematic review and meta-analysis. Neurol Sci 2020; 41:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wegelin J, McNamara P, Durso R, et al. Correlates of excessive daytime sleepiness in Parkinson's disease. Parkinsonism Relat Disord 2005; 11:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norlinah MI, Afidah KN, Noradina AT, et al. Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS. Parkinsonism Relat Disord 2009; 15:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nomura T, Inoue Y, Kobayashi M, et al. Characteristics of obstructive sleep apnea in patients with Parkinson's disease. J Neurol Sci 2013; 327:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cochen De Cock V, Bayard S, Jaussent I, et al. Daytime sleepiness in Parkinson's disease: a reappraisal. PLoS One 2014; 9:e107278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manni R, Terzaghi M, Repetto A, et al. Complex paroxysmal nocturnal behaviors in Parkinson's disease. Mov Disord 2010; 25:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neikrug AB, Liu L, Avanzino JA, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep 2014; 37:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 2014; 71:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Videnovic A, Lazar AS, Barker RA, Overeem S. 'The clocks that time us'--circadian rhythms in neurodegenerative disorders. Nat Rev Neurol 2014; 10:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng F, Cai Y, Hou Y, et al. Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 2021; 85:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jester DJ, Lee S, Molinari V, Volicer L. Cognitive deficits in Parkinson's disease with excessive daytime sleepiness: a systematic review. Aging Ment Health 2020; 24:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman JG, Ghode RA, Ouyang B, et al. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord 2013; 19:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poryazova R, Benninger D, Waldvogel D, Bassetti CL. Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants. Eur Neurol 2010; 63:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shpirer I, Miniovitz A, Klein C, et al. Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study. Mov Disord 2006; 21:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds GO, Otto MW, Ellis TD, Cronin-Golomb A. The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease. Mov Disord 2016; 31:23.
          </a>
         </li>
         <li class="breakAll">
          Go4Life from the National Institute on Aging at NIH: https://go4life.nia.nih.gov/how-exercise-helps/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corvol JC, Azulay JP, Bosse B, et al. THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. Mov Disord 2022; 37:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med 2021; 17:1895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012; 11:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012; 79:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial. Neurology 2017; 89:1795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Högl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Videnovic A, Amara AW, Comella C, et al. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord 2021; 36:2408.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 133139 Version 3.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19514014" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27863901" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17098844" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Insomnia in Parkinson's disease: frequency and progression over time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16602112" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16602112" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23643658" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Subjectively impaired bed mobility in Parkinson disease affects sleep efficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18359262" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17960797" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Nighttime sleep problems and daytime sleepiness in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28365203" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21836035" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16780888" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30746417" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23751512" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29322594" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34373044" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21312275" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Parkinson's disease sleep scale--validation of the revised version PDSS-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14746389" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Assessment of sleep and sleepiness in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2748771" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20931631" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Scales to assess sleep impairment in Parkinson's disease: critique and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32135452" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Sleep in Parkinson's disease: A systematic review and meta-analysis of polysomnographic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30653247" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9617717" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sleep disorders in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21699627" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30013321" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: Results from a 1-year, open-label extension of the RECOVER study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21080009" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404192" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17509486" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30099246" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27605426" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Deep brain stimulation and sleep-wake functions in Parkinson's disease: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33074192" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23311399" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25382161" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35429481" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19623435" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30303817" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34672847" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33389776" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21322021" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26626320" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32568113" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Management of Pain in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29756335" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28671395" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Treatment of Chronic Insomnia in Adults: ACP Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31746468" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson's disease: A focus on psychological and daytime functioning with a single-case design with multiple baselines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28765835" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cognitive behavioral therapy for insomnia in Parkinson's disease: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23561946" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29530365" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The effect of light exposure on insomnia and nocturnal movement in Parkinson's disease: an open label, retrospective, longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28241159" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34052783" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The effects of bright light therapy on depression and sleep disturbances in patients with Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32987321" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32092190" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404779" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084125" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Melatonin for sleep disturbances in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35185525" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Melatonin Treatment for Sleep Disorders in Parkinson's Disease: A Meta-Analysis and Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20589875" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29114733" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18852348" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32757413" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19858078" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26971528" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28364416" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Periodic Limb Movements During Sleep Mimicking REM Sleep Behavior Disorder: A New Form of Periodic Limb Movement Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16171244" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20191945" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Best practice guide for the treatment of REM sleep behavior disorder (RBD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31674060" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31035190" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32480307" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29482811" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Prevalence of restless legs syndrome in Parkinson's disease: a systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28827009" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Characterizing restless legs syndrome and leg motor restlessness in patients with Parkinson's disease: A multicenter case-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22076542" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Increased risk of leg motor restlessness but not RLS in early Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16092099" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Atypical parkinsonism of Japan: amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942122" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Case-control study of restless legs syndrome and quality of sleep in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24464648" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Primary sleep disorder prevalence in patients with newly diagnosed Parkinson’s disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24235892" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effects of sleep disorders on the non-motor symptoms of Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33296545" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33779875" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Sleep Disorders and Cognitive Dysfunctions in Parkinson's Disease: A Meta-Analytic Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31897944" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The relationship between obstructive sleep apnea and Parkinson's disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16154796" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Correlates of excessive daytime sleepiness in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19362875" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23462516" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Characteristics of obstructive sleep apnea in patients with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25198548" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Daytime sleepiness in Parkinson's disease: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20198716" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Complex paroxysmal nocturnal behaviors in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24470706" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24687146" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Sleep and circadian rhythm regulation in early Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25385339" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : 'The clocks that time us'--circadian rhythms in neurodegenerative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33637423" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31478402" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cognitive deficits in Parkinson's disease with excessive daytime sleepiness: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23735187" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20090346" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16773617" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26715466" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26715466" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34709684" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34743790" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679638" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22658702" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22855866" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Caffeine for treatment of Parkinson disease: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28954882" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12489899" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12621632" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16291885" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34191352" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
